stock ticker hero image

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
June 24, 2024 2:31 am ET
Delayed at least 20 minutes

View stock information

Latest news, events & financials

View all

Our pipeline shows our relentless pursuit of the next breakthrough.

Phase II programs
80+
Phase III programs
30+
Under review
10+
Illustration of leaders speaking on stage

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Girl getting blood pressure checked by health care professional

Sustainability

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our Impact Report 2022/2023

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories
Innovation

Our Q1 2024 earnings report

Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. “Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing […]

Read more

Next: Our Q1 2024 earnings report

Innovation

Celebrating the opening of our latest state-of-the-art facility

The FLEx Center will help us continue to harness the power of leading-edge science with agility

Read more

Next: Celebrating the opening of our latest state-of-the-art facility

Innovation

Why we’re expanding and investing in our research and discovery efforts

Our commitment to innovation helps ensure a brighter future for patients everywhere

Read more

Next: Why we’re expanding and investing in our research and discovery efforts

Innovation

Our Q1 2024 earnings report

Merck’s (NYSE: MRK) Q1 2024 results reflect continued strong growth in oncology and vaccines. Our company announced Q1 worldwide sales of $15.8 billion, an increase of 9% from Q1 2023. “Merck has begun 2024 with continuing momentum in our business. We are harnessing the power of innovation to advance our deep pipeline and are maximizing […]

Read more

Next: Our Q1 2024 earnings report

Innovation

Celebrating the opening of our latest state-of-the-art facility

The FLEx Center will help us continue to harness the power of leading-edge science with agility

Read more

Next: Celebrating the opening of our latest state-of-the-art facility

Innovation

Why we’re expanding and investing in our research and discovery efforts

Our commitment to innovation helps ensure a brighter future for patients everywhere

Read more

Next: Why we’re expanding and investing in our research and discovery efforts

Previous
Next

Unsubscribe from email alerts

Contact us banner image
For questions, please contact our team.

Contact investor relations